Latest Breaking News On - Allergopharma gmbh - Page 2 : comparemela.com

DGAP-News: Dermapharm Holding SE / Key word(s): Annual Results Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures 13.04.2021 / 07:30 Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures » Revenue and earnings up due to organic growth and successful acquisitions » Vaccine production to commence in May 2021 at Allergopharma s site in Reinbek » Consolidated revenue to grow by 24 % - 26 % in 2021 » Consolidated EBITDA to increase by 45 % - 50 % in 2021 » Dividend proposal of EUR 0.88 per share for 2020 Grünwald, 13 April 2021 - Dermapharm Holding SE ( Dermapharm ), a rapidly growing manufacturer of branded pharmaceuticals for selected therapeutic areas in Germany, today published its full Annual Report 2020. Dermapharm confirms its preliminary consolidated figures (IFRS) for financial year 2020. Both consolidated revenue and consolidated earnings continue on their clear growth trajectory. Gro

Sachsen anhaltSchleswig holsteinClaudius krauseHans georg feldmeierBritta hambergerMeeting of dermapharm holdingDermapharm groupAllergopharma gmbh coDermapharm holding seDermapharm holdingInvestor relations corporate communicationsAnnual reportAllergopharma gmbhGeneral meetingAnnual general meetingSupervisory board